C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 6.83 HKD -2.01% Market Closed
Market Cap: 2.2B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Cutia Therapeutics
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cutia Therapeutics
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
C
Cutia Therapeutics
HKEX:2487
Total Equity
ÂĄ1.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Equity
ÂĄ25.1B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Equity
ÂĄ12.4B
CAGR 3-Years
1%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Equity
ÂĄ12.7B
CAGR 3-Years
71%
CAGR 5-Years
57%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Equity
ÂĄ31.5B
CAGR 3-Years
26%
CAGR 5-Years
44%
CAGR 10-Years
29%
Imeik Technology Development Co Ltd
SZSE:300896
Total Equity
ÂĄ6.3B
CAGR 3-Years
12%
CAGR 5-Years
74%
CAGR 10-Years
N/A
No Stocks Found

Cutia Therapeutics
Glance View

Market Cap
2.1B HKD
Industry
Biotechnology

Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.

Intrinsic Value
11.5 HKD
Undervaluation 41%
Intrinsic Value
Price
C

See Also

What is Cutia Therapeutics's Total Equity?
Total Equity
1.3B CNY

Based on the financial report for Dec 31, 2023, Cutia Therapeutics's Total Equity amounts to 1.3B CNY.

Back to Top